Nomination Committee prior to Orexo’s 2010 Annual General Meeting

In accordance with the decision at the 2009 Annual General Meeting, the composition of the Nomination Committee for the 2010 Annual General Meeting is hereby announced. At Orexo’s Annual General Meeting on April 23, 2009, it was resolved that the company shall have a Nomination Committee consisting of one representative for each of the four largest shareholders in terms of the number of votes and the chairman of the Board of Directors. The Nomination Committee, whose tasks include providing proposals to the 2010 Annual General Meeting regarding Chairman of the Meeting, Board members, Chairman of the Board, board fees for the board members, remuneration for committee work, if any, fees to the company’s auditor as well as principles for composition of the Nomination Committee, comprises: • Björn Odlander, HealthCap, also Chairman of the Nomination Committee • Marc Philouze, Apax Partners • Antoine Papiernik, Sofinnova Partners • Ulrica Slåne, Third Swedish National Pension Fund (AP3) • Håkan Åström, Chairman of the Board of Orexo The Nomination Committee represents in total approximately 40 percent of the number of shares and votes in the company based on the most recent shareholder information known to Orexo. The Nomination Committee’s proposals will be presented in the Notice to the Annual General Meeting 2010 and on Orexo’s web site, www.orexo.com. Shareholders who want to submit proposals to the Nomination Committee, can do this by sending an e-mail to johan.andersson@orexo.com (subject “Nomination Committee”) or by letter posted to “Orexo’s Nomination Committee,” Orexo AB, Box 303, SE-751 05 Uppsala, Sweden, by March 3, 2010, at the latest. The Annual General Meeting in Orexo will be held on Wednesday, April 21, 2010 in Stockholm. Shareholders who want to have a matter addressed at the Annual General Meeting 2010 must submit such a proposal to the same address as above (subject “Annual General Meeting 2010” for the e-mail and the letter, respectively) in sufficient time prior to the announcement to convene the Meeting, which is expected to occur at the beginning of March 2010. Future information reporting dates from Orexo: Interim Report January – September 2009 November 10, 2009 Year-End Report 2009 February 17, 2010 Annual General Meeting 2010 April 21, 2010 Interim Report January – March 2010 May 5, 2010 Interim Report January – June 2010 August 20, 2010 Interim Report January – September 2010 November 10, 2010 For more information, please contact: Claes Wenthzel, Executive Vice President and CFO Tel: +46 (0)708-62 01 22 E-mail: claes.wenthzel@orexo.com Johan Andersson, Investor Relations Manager Tel: +46 (0)702-10 04 51 E-mail: johan.andersson@orexo.com Note: This is information that Orexo AB (publ) is required to disclose pursuant to the Swedish Financial Instruments Trading Act and/or the Swedish Securities Markets Act. The information was provided for public release on October 16th, 2009 at 08:00 CET.

Tags:

About Us

Orexo develops improved pharmaceuticals based on innovative drug delivery technologies.The focus is primarily on opioid dependence and pain but the aim is to address therapeutic areas where our competence and technologies can create value. The main market today is the US market for the treatment of opioid dependence where the product Zubsolv® is commercialized by Orexo. Other products are commercialized by license partners, including Zubsolv in markets outside of the US. Total net sales for 2016 amounted to SEK 705.9 million and the number of employees was 102. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) index and is available as ADRs on OTCQX (ORXOY) in the US. The head office, where also research and development is performed, is located in Uppsala, Sweden.

Subscribe

Documents & Links